WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Xi Stresses Contributing to Chinese Modernization with Solid ActionsXi extends New Year greetings to nonThere's spring in real estate recoveryScholars of South Sudan, China pledge collaboration for mutual developmentChina formally starts acrossXi Stresses HighXi Urges Young Officials to Take on Historical Task on New JourneyBridge on Xiong'an Expressway in placeChina's top diplomat to attend Munich Security Conference, visit Spain and FranceChina's foreign trade starts on steady note in 2023
2.8704s , 6496.21875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Imagery news portal